Why Testosterone Without Baseline Labs Is Medical Malpractice

The Testosterone Gap: Why Workup Matters

The data is uncomfortable: many men initiating testosterone replacement therapy (TRT) never receive comprehensive baseline endocrine assessment. This isn't just suboptimal—it's diagnostically blind.

Without proper workup, you're treating a number, not a patient. You're also missing concurrent pathology, drug interactions, and contraindications that could transform TRT from therapeutic to harmful.

What "Proper Workup" Actually Means

Baseline assessment for testosterone therapy requires more than a single serum testosterone level. Here's the clinical minimum:

Primary Hormonal Panel

Total testosterone: Measured via LC-MS/MS (liquid chromatography-tandem mass spectrometry), not immunoassay. Many labs still use inferior immunoassays, which introduce significant error at lower ranges (<300 ng/dL). Reference range varies by lab, but 264-916 ng/dL is standard; however, symptom correlation matters more than absolute numbers.

Free testosterone: Calculate using Vermeulen equation or measure via equilibrium dialysis. This is what binds to tissue—total testosterone is only a proxy. Many symptomatic hypogonadal men have normal total testosterone but low free testosterone (<50 pg/mL suggests investigation).

SHBG (sex hormone-binding globulin): Critical. High SHBG artificially lowers bioavailable testosterone. Estrogen, liver disease, hyperthyroidism, and certain medications elevate SHBG. Low SHBG (<10 nM/L) suggests insulin resistance, metabolic dysfunction, or polycystic ovary syndrome in women.

Estradiol (sensitive assay, LC-MS/MS): Men need this. Aromatization of exogenous testosterone to estradiol is dose-dependent. Elevated estradiol (>40 pg/mL) increases thrombotic risk, gynecomastia, and erectile dysfunction. Suppressed estradiol (<15 pg/mL) on therapy causes joint pain and mood dysregulation.

LH and FSH: These tell you why testosterone is low. Primary hypogonadism (testicular failure) shows high LH/FSH with low testosterone. Secondary hypogonadism (pituitary/hypothalamic) shows low LH/FSH with low testosterone. The distinction changes treatment strategy.

Critical Safety Workup

Complete metabolic panel: Baseline renal function (creatinine, eGFR), liver function (AST, ALT, bilirubin). Testosterone therapy can affect both; you need baseline to detect adverse changes.

CBC with differential: Testosterone stimulates erythropoiesis. Baseline hemoglobin/hematocrit required to monitor for polycythemia (>50-55% hematocrit is dangerous).

Lipid panel (fasted, 12 hours): Testosterone can decrease HDL cholesterol and increase LDL in some men. Baseline comparison is essential for risk-benefit analysis.

PSA (prostate-specific antigen) and digital rectal exam: Non-negotiable. While testosterone doesn't cause prostate cancer, it accelerates existing disease. Men with PSA >4 ng/mL or suspicious DRE should undergo urology evaluation before TRT initiation. Baseline PSA allows detection of absolute rise (>0.75 ng/mL/year suggests pathology).

Thyroid panel (TSH, free T4, free T3): Hypogonadism and hypothyroidism coexist frequently. Both cause fatigue, brain fog, and sexual dysfunction. Treating one while ignoring the other yields poor outcomes.

Prolactin: Elevated prolactin suppresses GnRH and therefore LH. If prolactin is high, investigate pituitary pathology before starting TRT.

Metabolic and Inflammatory Markers

Fasting glucose and HbA1c: Testosterone improves insulin sensitivity, but baseline assessment prevents misattribution of metabolic changes to therapy alone.

Fasting insulin: Reflects insulin resistance. Men with HOMA-IR >2.5 often benefit from concurrent berberine (500 mg BID) or metformin to enhance TRT response and mitigate cardiovascular risk.

hsCRP (high-sensitivity C-reactive protein): Baseline inflammation influences TRT tolerance and cardiovascular outcomes.

Why Doctors Skip Workup (And Why That's Inexcusable)

Reimbursement pressure: Comprehensive testing takes 30 minutes; many practices optimize for throughput, not outcomes.
Assumption of simplicity: "Low testosterone = give testosterone" ignores the endocrine axis complexity.
Liability avoidance (paradoxically): Ironically, not testing creates greater liability than proper assessment with shared decision-making.
Lab accessibility: Rural or underinsured patients may lack access to LC-MS/MS testosterone assays or specialty testing.

Interpreting Your Own Workup

Once you have labs:

Total T: Assess in context of free T and symptoms. A man with 600 ng/dL total but elevated SHBG may feel as poorly as one with 400 ng/dL and low SHBG.
Free T: More predictive of symptom improvement than total. Target 15-25 pg/mL on therapy for most men.
Estradiol: Sweet spot on TRT is 20-30 pg/mL. Below 15 causes joint and mood issues; above 40 increases thromboembolic risk.
SHBG: If >30 nM/L, address underlying causes (hyperthyroidism, hepatic disease) before escalating testosterone dose.
PSA trend: Absolute value matters less than velocity. A man with baseline PSA 2.5 ng/mL who rises to 4.0 ng/mL in one year requires urology referral.

What Happens When You Skip Workup

Missing baseline testing leaves you blind to:

Occult prostate cancer accelerated by TRT
Polycythemia developing silently until stroke risk spikes
Secondary hypogonadism due to pituitary pathology that needs MRI, not testosterone
Aromatization patterns that require estrogen management
Drug interactions (e.g., CYP3A4 inducers) that compromise TRT efficacy

Bottom Line

Testosterone therapy is legitimate and effective when indicated. But indication requires evidence. Proper workup—comprehensive hormonal assessment plus safety labs—isn't optional nicety; it's the foundation of safe, evidence-based practice. Any provider offering TRT without baseline testing isn't practicing medicine; they're practicing supply-side endocrinology.

Demand the workup. Your endocrine system, cardiovascular system, and prostate will thank you.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.